GLP-1 Access: AMA Urges Expanded Availability
- The American Medical Association (AMA) has approved a resolution designed to improve patient access to anti-obesity medications.
- The resolution addresses issues such as prior authorization requirements, where health care providers must obtain insurance plan approval before prescribing these medications.
- According to the Endocrine Society, which championed the resolution, improved access to anti-obesity medications could benefit the more than two in five adults in the U.S.
Teh American medical Association (AMA) is taking action to broaden patient access to anti-obesity medications. This crucial step, supported by the Endocrine Society, aims to streamline access to treatments, potentially lowering healthcare costs and benefiting the two in five US adults battling obesity. The resolution tackles prior authorization hurdles that currently impede access to essential treatments. Dr. Fatima Cody Stanford highlights GLP-1 receptor agonists as a promising pathway. While challenges remain, notably insurance resistance, the AMA plans to advocate for expanded coverage to streamline access. News Directory 3 reports on this impactful development. Further advocacy and research are paramount in effectively addressing obesity. Discover what’s next in the fight against obesity!
AMA Adopts Resolution to Expand Access to Anti-Obesity Drugs
The American Medical Association (AMA) has approved a resolution designed to improve patient access to anti-obesity medications. The move builds on existing AMA policies that advocate for better access to obesity treatments, including bariatric surgery.
The resolution addresses issues such as prior authorization requirements, where health care providers must obtain insurance plan approval before prescribing these medications. some insurers mandate prior authorization for every dose change, creating a burden for both patients and physicians.
According to the Endocrine Society, which championed the resolution, improved access to anti-obesity medications could benefit the more than two in five adults in the U.S. living with obesity. It may also reduce the $173 billion in annual obesity-related medical costs.
Dr. Amanda Bell, a House of Delegates representative for the Endocrine Society, noted that many health care providers hesitate to prescribe anti-obesity medications due to concerns about high pharmacy bills for patients. Removing barriers to access would allow more patients to receive the necessary care for this chronic disease.
The resolution also aims to eliminate insurance mandates that restrict patients to obtaining prescriptions solely from contracted disease management companies.
Dr. Fatima Cody Stanford, an obesity medicine physician scientist at Massachusetts General Hospital and Harvard Medical School, expressed support for the resolution, emphasizing its alignment with efforts to provide effective treatment options for obesity and its associated comorbidities. She highlighted the potential for GLP-1 receptor agonists to help patients achieve significant weight loss, reducing the risk of heart disease and diabetes.
While the resolution offers advantages such as improved patient access and potential cost reduction, Dr. Stanford acknowledged potential challenges. resistance from insurers due to medication costs and difficulties in implementing the resolution across various health care systems could pose problems. She also emphasized the importance of combining medication with lifestyle interventions for a extensive approach to obesity treatment.
Dr. Stanford stressed that continued advocacy and research are crucial to address the multifaceted factors contributing to obesity.
What’s next
The AMA will begin advocating for policies that reduce the burden of prior authorization and expand insurance coverage for anti-obesity medications. Further research and discussions are expected to address implementation challenges and ensure comprehensive obesity treatment strategies.